Next-Generation Cardiac Interfacing Technologies Using Nanomaterial-Based Soft Bioelectronics.
Sang Ihn HanSung-Hyuk SunwooChan Soon ParkSeung-Pyo LeeTaeghwan HyeonDae-Hyeong KimPublished in: ACS nano (2024)
Cardiac interfacing devices are essential components for the management of cardiovascular diseases, particularly in terms of electrophysiological monitoring and implementation of therapies. However, conventional cardiac devices are typically composed of rigid and bulky materials and thus pose significant challenges for effective long-term interfacing with the curvilinear surface of a dynamically beating heart. In this regard, the recent development of intrinsically soft bioelectronic devices using nanocomposites, which are fabricated by blending conductive nanofillers in polymeric and elastomeric matrices, has shown great promise. The intrinsically soft bioelectronics not only endure the dynamic beating motion of the heart and maintain stable performance but also enable conformal, reliable, and large-area interfacing with the target cardiac tissue, allowing for high-quality electrophysiological mapping, feedback electrical stimulations, and even mechanical assistance. Here, we explore next-generation cardiac interfacing strategies based on soft bioelectronic devices that utilize elastic conductive nanocomposites. We first discuss the conventional cardiac devices used to manage cardiovascular diseases and explain their undesired limitations. Then, we introduce intrinsically soft polymeric materials and mechanical restraint devices utilizing soft polymeric materials. After the discussion of the fabrication and functionalization of conductive nanomaterials, the introduction of intrinsically soft bioelectronics using nanocomposites and their application to cardiac monitoring and feedback therapy follow. Finally, comments on the future prospects of soft bioelectronics for cardiac interfacing technologies are discussed.
Keyphrases
- left ventricular
- cardiovascular disease
- drug delivery
- heart failure
- healthcare
- reduced graphene oxide
- primary care
- machine learning
- artificial intelligence
- mesenchymal stem cells
- metabolic syndrome
- cancer therapy
- gold nanoparticles
- atrial fibrillation
- coronary artery disease
- current status
- stress induced
- cell therapy
- replacement therapy